Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

PURPOSE Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth factor receptor 2 (HER2) positive. Because dual-agent HER2 blockade demonstrated a survival benefit in breast cancer, we conducted a phase II feasibility study of trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy (nCRT) in patients with EAC. PATIENTS AND METHODS Patients with…

Read the full article here

Source: Journal of Clinical Oncology

Categories: Hem/Onc News and Journals

Tags: esocsm

Tweets with this article

ASCO Publications

Trastuzumab and pertuzumab in HER2-positive esophageal cancer https://t.co/ZFXhxFz7fC #esocsm #JCO https://t.co/eVwcvoA4lG

PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma

PURPOSEMore than 30% of patients with pancreatic cancer are unresectable because of the local extension with a median overall survival (OS) of <1 year. Combination…

ASCO Publications May 21, 2025

Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia

PURPOSEThis randomized phase-II trial (ClinicalTrials.gov identifier: NCT02767557) compared efficacy of gemcitabine/nab-paclitaxel (Gem/Nab) with or without the anti–interleukin-6 (IL-6) receptor antibody tocilizumab (Toc) for advanced pancreatic…

ASCO Publications May 20, 2025

Tamales

@MissMeganEl shares a story reflecting on how patients invite us into their culture and their world and how this solidified her choice to be an…

ASCO Publications May 19, 2025

Financial Toxicity in Cancer Clinical Trials: An Issue in Need of Clarity and Solutions

The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of…

ASCO Publications May 19, 2025

Dose-Escalated Stereotactic Versus Conventional Radiotherapy for Painful Bone Metastases (ROBOMET): A Multicenter, Patient-Blinded Randomized Clinical Trial

PURPOSETo test whether dose-escalated single fraction (SF) stereotactic body radiotherapy (SBRT) of 20 Gy to painful bone metastases is superior to conventional SF three-dimensional (3D)…

ASCO Publications May 16, 2025

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial

PURPOSERandomized clinical trials (RCTs) have shown progression-free survival (PFS) benefits of metastasis-directed therapy (MDT) without androgen deprivation therapy for oligometastatic castration-sensitive prostate cancer (omCSPC). Most…

ASCO Publications May 15, 2025

Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy

PURPOSECisplatin treats many common tumors but causes permanent and debilitating hearing loss (HL). The objective of this study was to develop and externally validate a…

ASCO Publications May 14, 2025

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database

PURPOSESeveral lines of treatment can be used sequentially in patients with metastatic colorectal cancer. We investigated the evolution of patient/tumor characteristics and their prognostic impact…

ASCO Publications May 13, 2025

Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes

PURPOSETumor Protein 53 (p53) expressed from gene TP53 is a seminal tumor suppressor. We aimed to characterize mutational and nonmutational mechanisms of p53 dysfunction in…

ASCO Publications May 9, 2025

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates…

ASCO Publications May 6, 2025

Related Articles